GW completes Epidiolex submission

31st October 2017 Uncategorised 0

GW Pharmaceuticals and its US subsidiary Greenwich Biosciences have completed the rolling submission of Epidiolex as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two difficult-to-treat forms of childhood-onset epilepsy.

More: GW completes Epidiolex submission
Source: News